TrialScope Adds Another Clinical Trial Sponsor to Growing Customer Base
JERSEY CITY, N.J., May 28, 2015 –
The new account represents continued growth for TrialScope since the company acquired the PharmaCM platform in June 2014. Currently, over 8,000 users around the world are managing almost 30,000 clinical trial registrations using the PharmaCM platform.
Mike Forgash, CEO, TrialScope, commented, “The TrialScope team looks forward to working with a new sponsor team and adding to its growing roster of satisfied clients. Our expanding customer base is a testament to the simplicity, efficiency and overall value that our zero-footprint solutions bring to complex clinical trial disclosure processes. Our team’s strong reputation for depth of knowledge and breadth of experience is attractive to clients of all sizes who are looking to stay ahead of the curve regarding ever-changing global regulatory requirements and need a disclosure-driven solution as opposed to simply a technology. This is especially important as emerging regulations (such as the EU Clinical Trials Regulation) add complexity to global trial disclosure processes.”
Thomas Wicks, Chief Strategy Officer, noted that the TrialScope team is leveraging its “Rapid Path to Compliance,” a proven engagement methodology based on collaboration and compliance and focused on quickly implementing the PharmaCM platform and decreasing the client’s time to productivity. He added, “As new clients come aboard, we have a unique chance to partner with them to transform their business practices and lower risks of non-compliance. Our practical knowledge is baked into our Rapid Path to Compliance methodology so clients get the combined benefits of our experience and our technology platform to simplify compliance and increase productivity.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- How the NIMBLE Study Supported Adherence With Quarterly Dosing of Cemdisiran
September 18th 2025
- Everything to Know About FDA’s Push Towards Radical Transparency in 2025
September 17th 2025
- IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes
September 17th 2025
- Managing Background Therapies in the NIMBLE Phase III Trial
September 17th 2025